Hemophagocytic lymphohistiocytosis (HLH) is a multisystem disorder mediated by cytokine storm and is characterized by fever, pancytopenia and organomegaly with laboratory features like hyperferritinemia, hypertriglyceridemia and hypofibrinogenemia 1 .
Introduction:
HLH is a syndrome characterized by fever, pancytopenia, splenomegaly, and hemophagocytosis in bone marrow, liver, or lymph nodes. It can be classified as familial (primary) or acquired (secondary) HLH 1 . Acquired HLH is associated with several viral, bacterial, fungal and parasitic infections as also autoimmune diseases and malignancies. HLH needs to be differentiated from other conditions like Sepsis, SIRS, MODS and Macrophage activation syndrome which can mimic HLH, as the management strategies and outcome of each differ according to the etiology 3 .
Case Report:
History and examination: A 10-year-old boy was admitted with fever and progressive pallor of 1 month duration. Examination revealed significant pallor, ecchymotic patches on chest and abdomen with generalized anasarca. Abdominal examination showed hepatosplenomegaly with liver of 10 cm below costal margin and spleen of 6 cm below costal margin. Chest & Cardiovascular examination revealed cardiomegaly, bilateral gross pleural effusion. On investigation there was anaemia ,lymphopenia, thrombocytopenia, elevated Erythrocyte sedimentation rate (ESR), and high aspartate transaminase levels. Peripheral blood film showed microcytic hypochromic erythrocytes with hypersegmented polymorphs. Coagulation profile was deranged with prolonged PT and aPTT. Extensive infection workup was negative. Chest X-ray showed bilateral gross pleural effusion and ultrasound abdomen showed hepatosplenomegaly with gross ascites and bilateral pleural effusion. Bone marrow biopsy showed hemophagocytes and lymphohistiocytes.
Course and management: On Day 1, considering Pancytopenia possibility of infections and malignancy was kept at admission. Patient was started on IV Ceftriaxone and amikacin with supportive management in the form of Fresh frozen plasma, packed cell transfusion and Platelet components. On Day 3, on receiving bone marrow cytology report, the diagnosis of HLH was confirmed and the patient was started on IVIg for 5 doses, Injection Dexamethasone 10mg/m 2 /day was also started after which slight improvement was noted for a day or two. Soon there was worsening respiratory distress. Repeat chest radiography showed patchy areas of collapse and consolidation. Antibiotics were changed to injectable Vancomycin and Ceftazidime. On Day 8 of admission patient developed blood in stool, Hematuria, worsening of respiratory distress and tachycardia. Antibiotics were changed to Inj. Meropenem and Inj.Linezolid. Inj. Fluconazole and Inj. Clindamycin were also added. He also needed multiple packed red cell and platelet transfusions. However he kept on worsening to develop an episode of pulmonary hemorrhage after which he was put on ventilator support and ionotropic support. He succumbed to pulmonary hemorrhage with refractory shock with multiorgan dysfunction on day 10 of hospital stay.
Discussion:
Diagnosis of HLH is not in doubt in the index child as he did satisfy five clinical criteria for HLH: fever, splenomegaly, cytopenia involving two cell lines, high fasting triglycerides, high serum ferritin and bone marrow showing lymphohistiocytes. Ferritin levels more than 10,000 ng/ml have been found to be 98% specific for HLH in children 4 .
It is of two types -primary HLH4 and secondary HLH (acquired HLH), which occurs after strong immunologic activation by systemic infection (virus, bacteria and protozoa), autoimmune disorders or underlying malignancy 5 . In a majority of cases, HLH occurs secondary to one or more acquired triggers in a setting of genetic predisposition 6, 7 . EBV is said to be the most common acquired trigger 8 . The pathological hallmark of this disease is the aggressive proliferation of activated macrophages and histiocytes, which phagocytose other cells, namely red blood corpuscles (RBCs), white blood corpuscles (WBCs) and platelets, leading to the clinical symptoms 9 . 
